WeVote
Log In

Bill

Bill

HB 1120

Screening and approval program for retail sale of products containing certain substances; establish.

2025 Regular Session Introduced by Stacey Hobgood-Wilkes

Mississippi would create a state approval program requiring products containing certain substances to pass screening before retail sale, affecting consumer access and business compliance.

Died In Committee
#drugpolicy #publichealthandhumanservices
0
WeVote Research Nonpartisan
Bill Summary · HB 1120

Legislative bill overview

HB 1120 would establish a screening and approval program for retail products containing certain controlled or restricted substances in Mississippi. The bill creates a regulatory framework requiring products to meet state approval standards before being sold at retail locations. Specific substances subject to the program are not detailed in the available information.

Why is this important

This bill addresses concerns about unregulated products containing potentially harmful substances entering the retail market. Such screening programs affect consumer safety, business operations, and state regulatory capacity. The bill's impact depends heavily on which substances it targets—ranging from synthetic drugs to dietary supplements.

Potential points of contention

  • Regulatory scope uncertainty: Without knowing which specific substances are covered, businesses cannot assess compliance costs or feasibility
  • Implementation burden: Establishing an approval program requires significant state resources, testing infrastructure, and staff expertise
  • Industry impact: Retail businesses may face delays in product launches, increased operational costs, and potential liability questions depending on approval timelines
  • Federalism questions: Potential overlap with FDA regulation and whether state-level approval duplicates existing federal frameworks

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.